Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam, Dharmacon, CytRx

Premium

Alnylam Licenses Kreutzer-Limmer IP to Dharmacon

Alnylam Pharmaceuticals said this week that it has granted Dharmacon a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family.

Specific terms of the deal were not disclosed.

The European patent family, acquired by Alnylam through its merger with Ribopharma in July 2003, covers the use of siRNAs to mediate RNAi in mammalian cells. A key patent in the family, EP 1144623/WO 0044895, is currently being opposed by five companies: Sirna Therapeutics, Atugen, Aventis Pharma, Janssen Pharmaceutica, and AstraZeneca.

Isis Pharmaceuticals and Novartis had also been opposing the patent, but dropped their opposition after establishing partnerships with Alnylam.


CytRx Shares Regain Nasdaq Listing Compliance

CytRx said this week that it has regained full compliance for continued listing on the Nasdaq Capital Market by satisfying the $1 minimum bid price requirement for 10 consecutive market trading days.

According to the company, it was first notified on June 7 last year that its shares failed to meet the bid requirement and faced delisting. CytRx had until June 2 to regain compliance with the Nasdaq's $1 minimum bid price requirement.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.